2022 Volume 39 Issue 4 Pages 583-592
Fosravuconazole (NAILIN®), a novel triazole antifungal drug developed in Japan, has been used to treat onychomycosis since 2018. We conducted a real-world multicentric retrospective study of oral fosravuconazole therapy to assess its efficacy, safety, and consistency. In total, 350 patients were enrolled between June 2019 and April 2020. The treatment consistency rate was 83.4% at 12 weeks and 32.6% at 48 weeks. The clinical and complete cure rates after 48 weeks were 78.9% and 57.8%, respectively. Most patients were clinically cured at 36 weeks. The median treatment duration was 41.9 weeks. In total, 76 side effects were observed in 18.3% of patients (64/350) and 15 patients discontinued the treatment. However, there were no serious adverse drug reactions. Overall, our study reveals the therapeutic benefits of fosravuconazole, including high efficacy, tolerance, and consistency in real-world clinical practice, and suggests that short-duration fosravuconazole treatment may contribute to patient compliance and adherence.
